stockrow
Friday 6 November 2026
Export FTRE’s income statement to Excel — free account
Fortrea Holdings Inc.
FTRE Healthcare Biotechnology
Fortrea Holdings Inc.’s revenue for fiscal 2025 (year ended December 2025) was $2.7 billion, up 1.00% from fiscal 2024.
- Revenue
- −1.40%
- EPS
- +103.7%
- Free cash flow
- −34.0%
- Total debt
- −6.33%
Quarter to September 2026, against a year earlier
21.95
1.49
+7.28%
Follow FTRE
Alert me
| Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 | Dec '20 | |
|---|---|---|---|---|---|---|
Piotroski F-Score |
3 | 4 | — | — | — | — |
P/E ratio |
0.00 | 0.00 | 0.00 | 17.99 | 17.99 | 17.99 |
Altman Z-Score |
(0.34) | 0.90 | 1.50 | — | — | — |
P/S ratio |
0.58 | 0.62 | 1.08 | 0.00 | 0.00 | 0.00 |
Altman Z″-Score (non-manufacturers) |
(3.58) | (0.02) | 1.40 | 4.63 | — | — |
P/FCF ratio |
17.82 | 7.02 | 22.40 | 174.70 | 174.70 | 174.70 |
Beneish M-Score |
(4.60) | (3.53) | (3.32) | — | — | — |
P/Operating CF |
12.19 | 97.61 | 166.31 | (1,336.44) | (1,336.44) | (1,336.44) |
P/B ratio |
2.79 | 1.23 | 1.79 | 0.78 | 0.78 | 0.78 |
Price to Tangible BV |
0.00 | 0.00 | 0.00 | 0.78 | 0.78 | 0.78 |
EV/Sales |
0.90 | 0.99 | 1.60 | 0.00 | 0.00 | 0.00 |
EV/EBITDA |
742.92 | 0.00 | 31.68 | 0.00 | 0.00 | 0.00 |
EV/Operating CF |
21.60 | 10.18 | 26.98 | 30.64 | 30.64 | 30.64 |
EV/FCF |
27.76 | 11.25 | 33.26 | 171.23 | 171.23 | 171.23 |
Quick Ratio |
0.84 | 0.82 | 1.41 | 1.62 | 1.24 | — |
Current Ratio |
0.98 | 1.00 | 1.61 | 1.78 | 1.35 | — |
Net Debt/EBITDA |
266.13 | (19.73) | 10.34 | (0.17) | (0.06) | 0.00 |
Debt/Assets |
38.77% | 31.42% | 36.74% | 1.47% | 0.00% | — |
Debt/Equity |
1.87 | 0.83 | 0.93 | 0.02 | 0.00 | — |
Asset Turnover |
0.87 | 0.68 | 0.66 | 1.32 | 0.00 | 0.00 |
Operating CF/Net income |
(0.12) | (0.80) | (6.68) | 0.44 | 1.73 | (0.56) |
Capex/Depreciation |
(0.03) | (0.23) | (0.29) | (0.52) | (0.16) | 0.00 |
Interest Coverage |
(9.55) | (1.31) | 0.46 | 935.50 | 571.50 | — |
| (102.41%) | (21.36%) | (1.00%) | 5.64% | 0.00% | 0.00% | |
| (31.33%) | (8.30%) | (0.58%) | 8.68% | 0.00% | 0.00% | |
ROIC |
(37.83%) | (4.27%) | 0.63% | 3.55% | 0.00% | — |
Return on Tangible Assets |
(739.28%) | (211.94%) | (3.91%) | 26.12% | 21.59% | 0.00% |
Average Days of Receivables |
79.03 | 89.27 | 126.93 | 131.51 | 110.66 | 0.00 |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Selling, General and Administrative Expense of Revenue |
16.76% | 20.79% | 15.76% | 14.67% | 9.91% | 10.39% |
Intangible Assets out of Total Assets |
0.58 | 0.66 | 0.57 | 0.66 | 0.00 | — |
Share Based Compensation of Revenue |
2.73% | 2.17% | 1.50% | 0.90% | 0.90% | 0.00% |
Graham Net Nets |
(0.80) | (0.76) | (0.45) | 0.47 | 0.47 | 0.47 |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Earnings Yield |
(63.25%) | (19.79%) | (0.88%) | 5.56% | 5.56% | 5.56% |
Free Cash Flow Yield |
5.61% | 14.25% | 4.46% | 0.57% | 0.57% | 0.57% |
Revenue per Share |
29.86 | 30.13 | 32.01 | 31.95 | 34.43 | 28.99 |
Operating CF per Share |
1.24 | 2.94 | 1.90 | 0.93 | 1.91 | 2.26 |
Capex per Share |
(0.28) | (0.28) | (0.36) | (0.61) | (0.29) | 0.00 |
Free Cash Flow per Share |
0.97 | 2.66 | 1.54 | 0.32 | 1.62 | 2.26 |
Cash per Share |
1.91 | 1.32 | 1.22 | 1.26 | 1.07 | 0.00 |
Shareholders Equity per Share |
6.18 | 15.22 | 19.30 | 37.64 | 0.00 | 0.00 |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
6.18 | 15.22 | 19.30 | 37.64 | 0.00 | 0.00 |
Free Cash Flow |
88.30 | 237.80 | 136.60 | 28.70 | 143.60 | 200.90 |
Working Capital |
(16.10) | (1.30) | 472.40 | 547.90 | 291.00 | — |
Capital Expenditures |
(25.20) | (25.00) | (31.80) | (54.00) | (26.20) | (24.00) |
Net Current Asset Value |
(1,255.00) | (1,268.60) | (1,367.70) | 301.60 | 1,118.00 | — |
EV/EBIT |
0.00 | 0.00 | 141.98 | 0.00 | 0.00 | 0.00 |
Capex to Sales |
0.01 | 0.01 | 0.01 | 0.02 | 0.01 | 0.00 |
Price to Operating Income |
0.00 | 0.00 | 95.63 | 0.00 | 0.00 | 0.00 |
| Other line items | ||||||
Depreciation/Fixed assets |
5.86 | 0.71 | 0.65 | 0.63 | 1.02 | 0.00 |
Cash ROIC |
4.93% | 9.13% | 4.00% | 0.82% | 83.49% | 0.00% |
Accounts Receivable Turnover |
4.36 | 3.27 | 2.83 | 2.91 | 0.00 | 0.00 |
Accounts Payable Turnover |
26.44 | 15.95 | 21.01 | 29.65 | 0.00 | 0.00 |
Inventory Turnover |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Average Days of Payables |
4.88 | 23.33 | 21.54 | 14.08 | 9.08 | 0.00 |
Days of Inventory on Hand |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Average Receivables |
624.60 | 824.00 | 1,005.35 | 974.60 | — | — |
Average Payables |
83.95 | 135.55 | 107.20 | 71.25 | — | — |
Average Assets |
3,147.45 | 3,955.90 | 4,310.25 | 2,143.95 | — | — |
Average Common Equity |
962.95 | 1,538.25 | 2,528.35 | 3,301.80 | — | — |
Columns are period end dates · fundamentals updated 2 Nov 2026